Heartpoint Global Hopes To Disrupt Congenital Pulmonary Hypertension Treatment With Minimally Invasive Device
A new treatment under development by HeartPoint Global seeks to provide a minimally invasive and cheaper alternative to current treatments for pulmonary arterial hypertension.